People

Bob Elliott

Bob Elliott

Formal First Name
Robert (Bob)

Bob Elliott is the Co-Founder, CEO, and CIO of Unlimited Funds, which uses machine learning to create products that replicate the index returns of alternative investments. Elliott has built innovative hedge fund strategies for over two decades, most recently as Deputy CIO and member of the Investment Committee at Bridgewater Associates, the world’s largest hedge fund. At Bridgewater, he was responsible for the Pure Alpha foreign exchange portfolio from investment strategy to trade execution. He built and led Ray Dalio’s personal investment research team for nearly a decade, and was the author of hundreds of Bridgewater’s widely read Daily Observations. He also directly counselled some of the world's foremost policymakers and institutional investors on economic and investing issues. Elliott has also served as an advisor and executive at several startups including CircleUp, an investment company focused on early-stage consumer brands, where he led the strategy revamp for CircleUp’s venture capital business, improving predictive power of sourcing technology by 5x and driving alpha improvement with significantly faster deployment. He was also the co-founder of GiveWell, a startup charity evaluator which now directs more than $500mln in annual contributions.

Professional Experience


Academic History

BRIDGEWATER ASSOCIATES


CIRCLEUP

  • At CircleUp, Elliott increased accuracy of sourcing technology by 5x against quantitative and qualitative measures.

  • He developed an entirely new software revenue line leveraging Helio technology to partner with brand aggregators.

  • He also revamped the investment strategy for the company’s $150mln venture funds leveraging big data approaches to improve decision making.


ROIVANT SCIENCES

  • He led the firm's day-to-day executive, building an industry leading systematic approach to pharmaceutical commercialization.

  • He redesigned direct-to-consumer strategy, leveraging best practices across industries and achieving 2x pharmaceutical industry engagement.

  • He raised $150 million in external structured finance and equity commitments to pursue the acquisition of several external commercial-stage products.


MEDIA & APPEARANCES